Disc Medicine, Inc. (NASDAQ:IRON) Position Decreased by Sio Capital Management LLC

Sio Capital Management LLC decreased its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 2.1% in the 3rd quarter, Holdings Channel reports. The firm owned 187,941 shares of the company’s stock after selling 4,059 shares during the period. Disc Medicine comprises 3.7% of Sio Capital Management LLC’s investment portfolio, making the stock its 9th largest holding. Sio Capital Management LLC’s holdings in Disc Medicine were worth $9,235,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of IRON. Atlas Venture Life Science Advisors LLC lifted its position in Disc Medicine by 9.7% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 2,509,456 shares of the company’s stock valued at $113,101,000 after purchasing an additional 222,223 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its holdings in shares of Disc Medicine by 123.5% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock worth $79,090,000 after acquiring an additional 969,834 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its holdings in shares of Disc Medicine by 53.8% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock worth $46,119,000 after acquiring an additional 357,730 shares during the last quarter. Logos Global Management LP purchased a new position in Disc Medicine in the second quarter worth $41,690,000. Finally, Vanguard Group Inc. increased its stake in Disc Medicine by 2.4% in the first quarter. Vanguard Group Inc. now owns 782,751 shares of the company’s stock valued at $48,734,000 after acquiring an additional 18,207 shares during the last quarter. 83.70% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on IRON shares. Wedbush reiterated an “outperform” rating and issued a $83.00 price objective (up from $75.00) on shares of Disc Medicine in a report on Tuesday, November 12th. Wells Fargo & Company assumed coverage on Disc Medicine in a research note on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a research note on Tuesday, October 15th. Morgan Stanley raised shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective for the company in a research note on Tuesday, November 5th. Finally, Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $66.00 to $110.00 in a research report on Monday, November 4th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $85.80.

Disc Medicine Price Performance

Shares of Disc Medicine stock opened at $64.55 on Friday. The company’s fifty day simple moving average is $53.42 and its two-hundred day simple moving average is $46.92. Disc Medicine, Inc. has a 12-month low of $25.60 and a 12-month high of $77.60.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.15. As a group, equities analysts forecast that Disc Medicine, Inc. will post -4.05 EPS for the current fiscal year.

Insider Transactions at Disc Medicine

In other news, Director William Richard White sold 7,136 shares of the firm’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $58.61, for a total value of $418,240.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider William Jacob Savage sold 14,183 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $65.45, for a total transaction of $928,277.35. Following the transaction, the insider now owns 40,405 shares in the company, valued at $2,644,507.25. This represents a 25.98 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,879 shares of company stock worth $1,912,335. 4.24% of the stock is currently owned by insiders.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.